You just read:

AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids

News provided by

AbbVie

Apr 07, 2017, 08:00 ET